ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
최근, RTU 항체 시장 규모는 현저하게 확대되고 있습니다. 2024년 49억 1,000만 달러로 평가되었고, 2025년에는 53억 9,000만 달러에 달할 것으로 추정되며, CAGR 9.8%로 성장이 전망되고 있습니다. 지난 수년간의 성장은 면역 측정법의 채용 확대, 진단 용도에서의 이용 확대, 제약 및 바이오테크놀러지 분야에서 연구개발 활동의 활성화, 고품질 항체에 대한 수요 증가, 감염증 및 만성 질환의 유병률 상승에 기인한 것으로 보입니다.
RTU 항체 시장 규모는 향후 수년간 강력한 성장이 전망되고 있습니다. 2029년에는 77억 5,000만 달러에 달할 것으로 예측되며, CAGR 9.5%로 성장이 전망되고 있습니다. 향후 전망으로 예측 기간 성장은 맞춤형 의료에 대한 주목 강화, 바이오의약 연구에 대한 투자 증가, 신속하고 신뢰성 높은 진단 툴에 대한 수요 증가, 연구기관 및 바이오테크놀러지 기업 간 연계 강화, 실험실 프로세스에서 자동화 보급 확대에 의해 견인될 것으로 예측됩니다. 예측 기간 주요 동향으로는 항체 생산 플랫폼의 기술적 진보, 재조합 항체 공학의 혁신, 차세대 면역 측정 기술의 개발, 분석 최적화를 위한 디지털 기술 통합, 바이오테크놀러지 용도 분야에서의 지속적인 진전 등을 들 수 있습니다.
신속 진단 검사 및 맞춤형 의료에 대한 수요 증가가 향후 수년간 RTU 항체 시장의 확대를 이끌 것으로 예측됩니다. 신속 진단 검사 및 맞춤형 의료는 질병의 신속한 검출과 개인의 유전적, 분자적, 임상적 프로파일에 기초한 치료법의 최적화를 가능하게 하는 헬스케어 접근법을 말하며, 진단 정밀도 및 치료 성과를 모두 향상시킵니다. 이러한 접근법에 대한 수요 증가를 뒷받침하는 주요 요인은 헬스케어 시스템과 임상의가 환자 관리 및 치료 효과를 향상시키기 위해 보다 빠르고 정확한 진단 도구를 찾는 동안 전 세계적으로 질병의 조기 발견과 정밀의료로의 전환이 진행되고 있다는 것입니다. RTU 항체는 진단 및 맞춤형 치료 용도 분야에서 재현성, 신뢰성 및 효율성을 보장하는 검증된 고품질 시약을 제공함으로써 이러한 요구를 충족합니다. 예를 들어, 2024년 4월에는 스위스에 본부를 두고 있는 국제기구 '백신 얼라이언스(Gavi)'가 14개 저소득 국가를 향해 120만 건 이상의 신속 진단 키트를 출하했다고 보고했으며, 최초 배송은 2024년 4월 5일 말라위에 도착했습니다. 이러한 플랫폼 중 상당수는 항체 기반 기술에 의존하며 RTU 항체 시약 수요 증가를 부각하고 있습니다. 그 결과 신속 진단 검사와 맞춤형 의료에 대한 수요 증가가 RTU 항체 시장의 성장을 견인하고 있습니다.
RTU 항체 시장의 주요 기업은 연구 및 진단 용도 분야에서 항체 수율의 확장성, 순도 및 일관성을 향상시키기 위해 단일클론항체 생산 기술의 혁신에 주력하고 있습니다. 단일클론항체 생산은 B-림프구의 단일 클론으로부터 동일한 항체를 생성하는 생명공학 공정으로 진단, 치료 및 연구 용도에 있어서 균일한 구조, 높은 특이성, 신뢰성이 높은 성능을 보장합니다. 예를 들어, 2023년 3월에는 영국에 거점을 둔 생명과학 툴 기업인 Aptamer Group사가 자동 면역조직화학(IHC) 워크플로우에서 기존의 1차 검출 항체를 대체하는 혁신적인 시약 'Optimer-Fc'를 발표했습니다. 이 플랫폼은 Optimer 바인더와 항체 Fc 도메인을 통합하여 높은 선택성, 조절 가능한 결합 특성 및 최소 변동성을 제공합니다. 이 혁신은 신규성, 특허 취득 가능성, 재현성을 갖춘 IHC 시약에 대한 수요의 고조에 대응하고, 진단 정밀도를 향상시키는 것과 동시에, RTU 항체 시장에서 항체 대체 기술의 진전에 공헌하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향 및 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁 및 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석 및 전략 분석 프레임워크
세계의 RTU 항체 시장 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인 및 억제요인)
최종 이용 산업의 분석
세계의 RTU 항체 시장 : 성장률 분석
세계의 RTU 항체 시장 실적 : 규모 및 성장(2019-2024년)
세계의 RTU 항체 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
세계의 RTU 항체 시장 : 총 잠재 시장 규모(TAM)
제6장 시장 세분화
세계의 RTU 항체 시장 : 유형별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
항균 항체
항바이러스 항체
항독소
기타 유형
세계의 RTU 항체 시장 : 소스별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
동물 유래
인간 유래
합성
세계의 RTU 항체 시장 : 용도별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
병원
클리닉
기타 용도
세계의 RTU 항체 시장 : 최종 용도별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
제약기업
학술기관
수탁연구기관
세계의 RTU 항체 시장 : 항균 항체 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
그람 양성균 표적 항체
그람 음성균 표적 항체
광역 항균 항체
항생제 내성 표적 항체
세계의 RTU 항체 시장 : 항바이러스 항체 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
코로나 바이러스 중화 항체
인플루엔자 바이러스 중화 항체
인간 면역결핍 바이러스 중화 항체
간염 바이러스 중화 항체
세계의 RTU 항체 시장 : 항독소 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
세균 독소 중화 항체
사독 중화 항체
보툴리눔툭신(보톡스) 중화 항체
디프테리아 독소 중화 항체
세계의 RTU 항체 시장 : 기타 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
항기생충 항체
자가면역질환 표적 항체
알레르기 중화 항체
염증성 질환 표적 항체
제7장 지역별 및 국가별 분석
세계의 RTU 항체 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
세계의 RTU 항체 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도 및 기업 프로파일
RTU 항체 시장 : 경쟁 구도
RTU 항체 시장 : 기업 프로파일
Roche Diagnostics : 개요, 제품 및 서비스, 전략 및 재무 분석
Merck : 개요, 제품 및 서비스, 전략 및 재무 분석
Thermo Fisher Scientific : 개요, 제품 및 서비스, 전략 및 재무 분석
Becton Dickinson(BD) : 개요, 제품 및 서비스, 전략 및 재무 분석
Agilent Technologies : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Bio-Rad Laboratories
Bio-Techne
Leica Biosystems
Elabscience
GenScript
Cell Signaling Technology
RayBiotech Life
Santa Cruz Biotechnology
Rockland Immunochemicals
Creative Diagnostics
Jackson ImmunoResearch
Abnova Corporation
Southern Biotech
Diagnostic Biosystems
Boster Biological Technology
제32장 세계 시장 경쟁 벤치마킹 및 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문 및 전략
RTU 항체 시장(2009년) : 새로운 기회를 제공하는 국가
RTU 항체 시장(2009년) : 새로운 기회를 제공하는 부문
RTU 항체 시장(2009년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
AJY
영문 목차
영문목차
Ready-to-use antibodies are pre-diluted antibody solutions manufactured for immediate application in laboratory assays. They remove the need for additional dilution or preparation, providing convenience, consistency, and reliable experimental outcomes. Their main purpose is to save time, reduce human error, and ensure standardized, reproducible results in both diagnostic and research settings.
The main types of ready-to-use antibodies include antibacterial antibodies, antiviral antibodies, antitoxins, and others. An antibacterial antibody is a pre-validated, laboratory-prepared antibody formulated to specifically recognize and bind to bacterial antigens, enabling fast and accurate detection and analysis of bacterial infections in diagnostic and research applications. These antibodies come from various sources, including animal-based, human-based, and synthetic, and are used in settings such as hospitals, clinics, and other facilities. Key end users include pharmaceutical companies, academic institutions, and contract research organizations.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.
The ready-to-use antibodies market research report is one of a series of new reports from The Business Research Company that provides ready-to-use antibodies market statistics, including ready-to-use antibodies industry global market size, regional shares, competitors with a ready-to-use antibodies market share, detailed ready-to-use antibodies market segments, market trends and opportunities, and any further data you may need to thrive in the ready-to-use antibodies industry. This ready-to-use antibodies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The ready-to-use antibodies market size has grown strongly in recent years. It will grow from $4.91 billion in 2024 to $5.39 billion in 2025 at a compound annual growth rate (CAGR) of 9.8%. The growth during the historical period can be attributed to the increasing adoption of immunoassay techniques, their expanding use in diagnostic applications, rising pharmaceutical and biotechnology R&D activities, a growing demand for high-quality antibodies, and the rising prevalence of infectious and chronic diseases.
The ready-to-use antibodies market size is expected to see strong growth in the next few years. It will grow to $7.75 billion in 2029 at a compound annual growth rate (CAGR) of 9.5%. Looking ahead, the growth in the forecast period is expected to be driven by a stronger focus on personalized medicine, increased investments in biopharmaceutical research, rising demand for rapid and reliable diagnostic tools, growing collaborations between research institutes and biotech companies, and greater adoption of automation in laboratory processes. Key trends in the forecast period include technological advancements in antibody production platforms, innovations in recombinant antibody engineering, the development of next-generation immunoassay technologies, the integration of digital technologies for assay optimization, and ongoing advances in biotechnology applications.
The growing demand for rapid diagnostic tests and personalized medicine is expected to drive the expansion of the ready-to-use antibodies market in the coming years. Rapid diagnostic tests and personalized medicine refer to healthcare approaches that enable the quick detection of diseases and the tailoring of treatments based on an individual's genetic, molecular, or clinical profile, improving both diagnostic accuracy and treatment outcomes. A key factor fueling the increasing demand for these approaches is the global shift towards early disease detection and precision therapy, as healthcare systems and clinicians look for faster and more accurate diagnostic tools to improve patient management and treatment effectiveness. Ready-to-use antibodies meet this need by offering validated, high-quality reagents that ensure reproducibility, reliability, and efficiency in diagnostic testing and personalized therapeutic applications. For example, in April 2024, Gavi, the Vaccine Alliance, a Switzerland-based international organization, reported shipping over 1.2 million rapid diagnostic tests to 14 lower-income countries, with the first deliveries arriving in Malawi on April 5, 2024. Many of these platforms depend on antibody-based technologies, highlighting the growing need for ready-to-use antibody reagents. As a result, the increasing demand for rapid diagnostic tests and personalized medicine is propelling the growth of the ready-to-use antibodies market.
Major players in the ready-to-use antibodies market are focusing on innovations in monoclonal antibody production to improve scalability, purity, and consistency in antibody yield for research and diagnostic applications. Monoclonal antibody production involves the biotechnological process of creating identical antibodies derived from a single clone of B lymphocytes, ensuring uniform structure, high specificity, and reliable performance across diagnostic, therapeutic, and research uses. For instance, in March 2023, Aptamer Group, a UK-based life sciences tools company, introduced Optimer-Fc, an innovative reagent designed to replace traditional primary detecting antibodies in automated immunohistochemistry (IHC) workflows. The platform integrates an Optimer binder with an antibody Fc domain, offering high selectivity, tunable binding characteristics, and minimal variability. This innovation addresses the growing demand for novel, patentable, and reproducible IHC reagents, improving diagnostic precision and advancing antibody replacement technologies within the ready-to-use antibodies market.
In June 2024, Johnson & Johnson, a US-based healthcare, medical devices, and pharmaceutical company, acquired Proteologix, Inc. for $850 million. This acquisition allows Johnson & Johnson to expand its immunology portfolio and strengthen its capabilities in developing bispecific antibody therapeutics targeting immune-mediated diseases such as atopic dermatitis and asthma. Proteologix, Inc. is a US-based biotechnology company focused on preclinical bispecific antibody programs that target multiple disease pathways in a range of immune-mediated disorders.
Major companies operating in the ready-to-use antibodies market are Roche Diagnostics, Merck, Thermo Fisher Scientific, Becton Dickinson (BD), Agilent Technologies, Bio-Rad Laboratories, Bio-Techne, Leica Biosystems, Elabscience, GenScript, Cell Signaling Technology, RayBiotech Life, Santa Cruz Biotechnology, Rockland Immunochemicals, Creative Diagnostics, Jackson ImmunoResearch, Abnova Corporation, Southern Biotech, Diagnostic Biosystems, Boster Biological Technology
North America was the largest region in the ready-to-use antibodies market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in ready-to-use antibodies report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the ready-to-use antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The ready-to-use antibodies market consists of sales of primary antibodies, secondary antibodies, recombinant antibodies, polyclonal antibodies, monoclonal antibodies, fluorophore-conjugated antibodies, enzyme-conjugated antibodies, label-free antibodies, and isotype control antibodies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Ready-To-Use Antibodies Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on ready-to-use antibodies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for ready-to-use antibodies ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The ready-to-use antibodies market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Types: Antibacterial Antibody; Antiviral Antibody; Antitoxin; Other Types
2) By Source: Animal Based; Human Based; Synthetic
3) By Application: Hospital; Clinic; Other Applications
4) By End Use: Pharmaceutical Companies; Academic Institutions; Contract Research Organizations
3. Ready-To-Use Antibodies Market Trends And Strategies
4. Ready-To-Use Antibodies Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Ready-To-Use Antibodies Growth Analysis And Strategic Analysis Framework
5.1. Global Ready-To-Use Antibodies PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Ready-To-Use Antibodies Market Growth Rate Analysis
5.4. Global Ready-To-Use Antibodies Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Ready-To-Use Antibodies Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Ready-To-Use Antibodies Total Addressable Market (TAM)
6. Ready-To-Use Antibodies Market Segmentation
6.1. Global Ready-To-Use Antibodies Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Antibacterial Antibody
Antiviral Antibody
Antitoxin
Other Types
6.2. Global Ready-To-Use Antibodies Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Animal Based
Human Based
Synthetic
6.3. Global Ready-To-Use Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital
Clinic
Other Applications
6.4. Global Ready-To-Use Antibodies Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pharmaceutical Companies
Academic Institutions
Contract Research Organizations
6.5. Global Ready-To-Use Antibodies Market, Sub-Segmentation Of Antibacterial Antibody, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Gram-Positive Targeting Antibodies
Gram-Negative Targeting Antibodies
Broad-Spectrum Antibacterial Antibodies
Antibiotic-Resistance Targeting Antibodies
6.6. Global Ready-To-Use Antibodies Market, Sub-Segmentation Of Antiviral Antibody, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Coronavirus Neutralizing Antibodies
Influenza Virus Neutralizing Antibodies
Human Immunodeficiency Virus Neutralizing Antibodies
Hepatitis Virus Neutralizing Antibodies
6.7. Global Ready-To-Use Antibodies Market, Sub-Segmentation Of Antitoxin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Bacterial Toxin Neutralizing Antibodies
Snake Venom Neutralizing Antibodies
Botulinum Toxin Neutralizing Antibodies
Diphtheria Toxin Neutralizing Antibodies
6.8. Global Ready-To-Use Antibodies Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Anti-Parasitic Antibodies
Autoimmune Disease Targeting Antibodies
Allergy Neutralizing Antibodies
Inflammatory Disease Targeting Antibodies
7. Ready-To-Use Antibodies Market Regional And Country Analysis
7.1. Global Ready-To-Use Antibodies Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Ready-To-Use Antibodies Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
